B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia

Cancer

Volumn 117, Issue 9, 2011, Pages 1891-1900

  Binder, Mascha ^a   Müller, Fabian ^a   Jackst, Antje ^a   Léchenne, Barbara ^a   Pantic, Milena ^b   Bacher, Ulrike ^a   Zu Eulenburg, Christine ^a   Veelken, Hendrik ^b   Mertelsmann, Roland ^b   Pasqualini, Renata ^c   Arap, Wadih ^c   Trepel, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

B cell receptor; chronic lymphocytic leukemia; epitope recognition; phage display; polyreactivity

Indexed keywords

B LYMPHOCYTE RECEPTOR; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PHAGE DISPLAY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; RISK FACTOR;

DISEASE PROGRESSION; EPITOPES, B-LYMPHOCYTE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PEPTIDE LIBRARY; RECEPTORS, ANTIGEN, B-CELL;

EID: 79955433190     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25755     Document Type: Article

References (49)

1. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994; 8: 1640-1645. (Pubitemid 24323778)
2. Chiorazzi N, Ferrarini M., B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003; 21: 841-894. (Pubitemid 37174549)
3. Stevenson FK, Caligaris-Cappio F., Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004; 103: 4389-4395. (Pubitemid 38745961)
4. Tobin G., The immunoglobulin genes: structure and specificity in chronic lymphocytic leukemia. Leuk Lymphoma. 2007; 48: 1081-1086. (Pubitemid 47009198)
5. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007; 109: 259-270. (Pubitemid 46070124)
6. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004; 200: 519-525. (Pubitemid 39121908)
7. Tobin G, Rosen A, Rosenquist R., What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia? Hematol Oncol. 2006; 24: 7-13.
8. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM., The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas [serial online]. PLoS Biol. 2008; 6: e152.
9. Stamatopoulos K, Belessi C, Hadzidimitriou A, et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood. 2005; 106: 3575-3583. (Pubitemid 41609196)
10. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998; 102: 1515-1525. (Pubitemid 28492218)
11. Ghiotto F, Fais F, Albesiano E, et al. Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. Mol Med. 2006; 12: 300-308. (Pubitemid 46489823)
12. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008; 111: 1524-1533. (Pubitemid 351213442)
13. Bomben R, Dal Bo M, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol. 2009; 144: 492-506.
14. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006; 107: 2889-2894.
15. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003; 101: 4952-4957. (Pubitemid 36857759)
16. Hadzidimitriou A, Darzentas N, Murray F, et al. Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood. 2009; 113: 403-411.
17. Chiorazzi N, Hatzi K, Albesiano E., B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci. 2005; 1062: 1-12.
18. Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood. 2008; 112: 5122-5129.
19. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized-LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008; 111: 3838-3848.
20. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med. 2008; 14: 665-674.
21. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005; 105: 4820-4827. (Pubitemid 40807309)
22. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001; 98: 3050-3057.
23. Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med. 1989; 169: 255-268. (Pubitemid 19035555)
24. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest. 2005; 115: 1636-1643. (Pubitemid 40814672)
25. Seiler T, Woelfle M, Yancopoulos S, et al. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood. 2009; 114: 3615-3624.
26. Smith GP, Scott JK., Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993; 217: 228-257.
27. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M., The epitope recognized by rituximab. Blood. 2006; 108: 1975-1978. (Pubitemid 44395009)
28. Binder M, Votle FN, Michelfelder S, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 2007; 67: 3518-3523. (Pubitemid 46762130)
29. Perosa F, Favoino E, Caragnano MA, Dammacco F., CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases. Ann N Y Acad Sci. 2005; 1051: 672-683. (Pubitemid 41362795)
30. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E., Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol Immunol. 2005; 42: 1121-1124.
31. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003; 21: 57-63. (Pubitemid 36055828)
32. Vidal CI, Mintz PJ, Lu K, et al. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene. 2004; 23: 8859-8867. (Pubitemid 39657776)
33. Buhl L, Szecsi PB, Gisselo GG, Schafer-Nielsen C., Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia. Br J Haematol. 2002; 116: 549-554. (Pubitemid 34178653)
34. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94: 1848-1854. (Pubitemid 29430400)
35. Bertinetti C, Simon F, Zirlik K, et al. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol. 2006; 77: 395-402. (Pubitemid 44483942)
36. Osterroth F, Alkan O, Mackensen A, et al. Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J Immunol Methods. 1999; 229: 141-153. (Pubitemid 29505190)
37. Braren I, Greunke K, Umland O, Deckers S, Bredehorst R, Spillner E., Comparative expression of different antibody formats in mammalian cells and Pichia pastoris. Biotechnol Appl Biochem. 2007; 47 (pt 4): 205-214. (Pubitemid 47218255)
38. Jager S, Jahnke A, Wilmes T, et al. Leukemia-targeting ligands isolated from phage-display peptide libraries. Leukemia. 2007; 21: 411-420.
39. Trepel M, Arap W, Pasqualini R., Modulation of the immune response by systemic targeting of antigens to lymph nodes. Cancer Res. 2001; 61: 8110-8112. (Pubitemid 33091599)
40. Trepel M, Arap W, Pasqualini R., In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol. 2002; 6: 399-404. (Pubitemid 34522068)
41. Muller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. 2003; 21: 1040-1046. (Pubitemid 37064733)
42. Michelfelder S, Lee MK, DeLima-Hahn E, et al. Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol. 2007; 35: 1766-1776. (Pubitemid 350117116)
43. Michelfelder S, Kohlschutter J, Skorupa A, et al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries [serial online]. PLoS One. 2009; 4: e5122.
44. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W., Biopanning and rapid analysis of selective interactive ligands. Nat Med. 2001; 7: 1249-1253. (Pubitemid 33063782)
45. Ghia EM, Jain S, Widhopf GF, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal-center leukemogenic selection. Blood. 2008; 111: 5101-5108.
46. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008; 112: 188-195.
47. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008; 112: 782-792.
48. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G., Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003; 101: 1087-1093. (Pubitemid 36139383)
49. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK., Reversible anergy of sIgM-mediated signaling in the 2 subsets of CLL defined by VH-gene mutational status. Blood. 2007; 109: 4424-4431. (Pubitemid 46743412)